NASDAQ:CCXIChemoCentryx Stock Price, Forecast & News

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CCXI stock has increased by 43.7% and is now trading at $59.70. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ChemoCentryx.

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for ChemoCentryx.

ChemoCentryx Inc (NASDAQ:CCXI) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.05. The biopharmaceutical company had revenue of $6.01 million for the quarter, compared to analysts' expectations of $8.90 million. ChemoCentryx had a negative return on equity of 100.55% and a negative net margin of 192.93%. View ChemoCentryx's earnings history.

9 analysts have issued 1-year price targets for ChemoCentryx's shares. Their forecasts range from $54.00 to $102.00. On average, they expect ChemoCentryx's share price to reach $70.11 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View analysts' price targets for ChemoCentryx.

News coverage about CCXI stock has trended negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ChemoCentryx earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about ChemoCentryx.

ChemoCentryx saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,980,000 shares, an increase of 5.0% from the June 15th total of 3,790,000 shares. Based on an average trading volume of 697,800 shares, the short-interest ratio is currently 5.7 days. Currently, 8.4% of the company's stock are sold short. View ChemoCentryx's Current Options Chain.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Dynavax Technologies (DVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Arrowhead Pharmaceuticals (ARWR), Advanced Micro Devices (AMD), Opko Health (OPK), NVIDIA (NVDA) and Inovio Pharmaceuticals (INO).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.01%), Envestnet Asset Management Inc. (0.01%) and Exane Derivatives (0.00%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View institutional ownership trends for ChemoCentryx.

CCXI stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, and Thomas J Schall. View insider buying and selling activity for ChemoCentryx.

CCXI stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Envestnet Asset Management Inc.. View insider buying and selling activity for ChemoCentryx.

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CCXI stock can currently be purchased for approximately $59.70.

ChemoCentryx has a market capitalization of $3.69 billion and generates $36.13 million in revenue each year. The biopharmaceutical company earns $-55,490,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. ChemoCentryx employs 82 workers across the globe.

The official website for ChemoCentryx is www.chemocentryx.com.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]